vs

Side-by-side financial comparison of News Corp (Class A) (NWSA) and Regeneron Pharmaceuticals (REGN). Click either name above to swap in a different company.

Regeneron Pharmaceuticals is the larger business by last-quarter revenue ($3.9B vs $2.4B, roughly 1.6× News Corp (Class A)). Regeneron Pharmaceuticals runs the higher net margin — 21.7% vs 8.2%, a 13.6% gap on every dollar of revenue. On growth, News Corp (Class A) posted the faster year-over-year revenue change (5.5% vs 2.5%). Regeneron Pharmaceuticals produced more free cash flow last quarter ($922.0M vs $132.0M). Over the past eight quarters, Regeneron Pharmaceuticals's revenue compounded faster (11.1% CAGR vs -1.3%).

News is information about current events. This may be provided through many different media: word of mouth, printing, postal systems, broadcasting, electronic communication, or through the testimony of observers and witnesses to events. News is sometimes called "hard news" to differentiate it from soft media.

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.

NWSA vs REGN — Head-to-Head

Bigger by revenue
REGN
REGN
1.6× larger
REGN
$3.9B
$2.4B
NWSA
Growing faster (revenue YoY)
NWSA
NWSA
+3.0% gap
NWSA
5.5%
2.5%
REGN
Higher net margin
REGN
REGN
13.6% more per $
REGN
21.7%
8.2%
NWSA
More free cash flow
REGN
REGN
$790.0M more FCF
REGN
$922.0M
$132.0M
NWSA
Faster 2-yr revenue CAGR
REGN
REGN
Annualised
REGN
11.1%
-1.3%
NWSA

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
NWSA
NWSA
REGN
REGN
Revenue
$2.4B
$3.9B
Net Profit
$193.0M
$844.6M
Gross Margin
Operating Margin
22.7%
Net Margin
8.2%
21.7%
Revenue YoY
5.5%
2.5%
Net Profit YoY
-10.2%
-8.0%
EPS (diluted)
$0.34
$7.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NWSA
NWSA
REGN
REGN
Q4 25
$2.4B
$3.9B
Q3 25
$2.1B
$3.8B
Q2 25
$1.6B
$3.7B
Q1 25
$2.0B
$3.0B
Q4 24
$2.2B
$3.8B
Q3 24
$2.6B
$3.7B
Q2 24
$2.6B
$3.5B
Q1 24
$2.4B
$3.1B
Net Profit
NWSA
NWSA
REGN
REGN
Q4 25
$193.0M
$844.6M
Q3 25
$112.0M
$1.5B
Q2 25
$743.0M
$1.4B
Q1 25
$103.0M
$808.7M
Q4 24
$215.0M
$917.7M
Q3 24
$119.0M
$1.3B
Q2 24
$50.0M
$1.4B
Q1 24
$30.0M
$722.0M
Operating Margin
NWSA
NWSA
REGN
REGN
Q4 25
22.7%
Q3 25
27.3%
Q2 25
8.5%
29.4%
Q1 25
7.5%
19.5%
Q4 24
19.2%
26.1%
Q3 24
7.9%
31.7%
Q2 24
4.3%
30.2%
Q1 24
2.6%
23.9%
Net Margin
NWSA
NWSA
REGN
REGN
Q4 25
8.2%
21.7%
Q3 25
5.2%
38.9%
Q2 25
45.6%
37.9%
Q1 25
5.1%
26.7%
Q4 24
9.6%
24.2%
Q3 24
4.6%
36.0%
Q2 24
1.9%
40.4%
Q1 24
1.2%
23.0%
EPS (diluted)
NWSA
NWSA
REGN
REGN
Q4 25
$0.34
$7.78
Q3 25
$0.20
$13.62
Q2 25
$1.30
$12.81
Q1 25
$0.18
$7.27
Q4 24
$0.38
$8.12
Q3 24
$0.21
$11.54
Q2 24
$0.09
$12.41
Q1 24
$0.05
$6.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NWSA
NWSA
REGN
REGN
Cash + ST InvestmentsLiquidity on hand
$2.1B
$8.6B
Total DebtLower is stronger
$2.0B
Stockholders' EquityBook value
$8.8B
$31.3B
Total Assets
$15.5B
$40.6B
Debt / EquityLower = less leverage
0.22×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NWSA
NWSA
REGN
REGN
Q4 25
$2.1B
$8.6B
Q3 25
$2.2B
$8.4B
Q2 25
$2.4B
$7.5B
Q1 25
$2.1B
$8.3B
Q4 24
$1.8B
$9.0B
Q3 24
$1.8B
$9.8B
Q2 24
$2.0B
$9.8B
Q1 24
$1.9B
$10.5B
Total Debt
NWSA
NWSA
REGN
REGN
Q4 25
$2.0B
Q3 25
$2.0B
Q2 25
$2.0B
Q1 25
$2.0B
Q4 24
$2.0B
Q3 24
$2.9B
Q2 24
$2.9B
Q1 24
$2.9B
Stockholders' Equity
NWSA
NWSA
REGN
REGN
Q4 25
$8.8B
$31.3B
Q3 25
$8.7B
$31.0B
Q2 25
$8.8B
$29.9B
Q1 25
$8.2B
$29.4B
Q4 24
$8.1B
$29.4B
Q3 24
$8.3B
$29.3B
Q2 24
$8.1B
$28.2B
Q1 24
$8.1B
$27.0B
Total Assets
NWSA
NWSA
REGN
REGN
Q4 25
$15.5B
$40.6B
Q3 25
$15.3B
$40.2B
Q2 25
$15.5B
$38.2B
Q1 25
$16.6B
$37.5B
Q4 24
$16.2B
$37.8B
Q3 24
$16.9B
$37.4B
Q2 24
$16.7B
$36.1B
Q1 24
$16.5B
$34.4B
Debt / Equity
NWSA
NWSA
REGN
REGN
Q4 25
0.22×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.24×
Q4 24
0.24×
Q3 24
0.35×
Q2 24
0.36×
Q1 24
0.36×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NWSA
NWSA
REGN
REGN
Operating Cash FlowLast quarter
$231.0M
$1.2B
Free Cash FlowOCF − Capex
$132.0M
$922.0M
FCF MarginFCF / Revenue
5.6%
23.7%
Capex IntensityCapex / Revenue
4.2%
6.4%
Cash ConversionOCF / Net Profit
1.20×
1.39×
TTM Free Cash FlowTrailing 4 quarters
$586.0M
$4.1B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NWSA
NWSA
REGN
REGN
Q4 25
$231.0M
$1.2B
Q3 25
$85.0M
$1.6B
Q2 25
$189.0M
$1.1B
Q1 25
$511.0M
$1.0B
Q4 24
$252.0M
$1.3B
Q3 24
$64.0M
$1.3B
Q2 24
$254.0M
$354.0M
Q1 24
$539.0M
$1.5B
Free Cash Flow
NWSA
NWSA
REGN
REGN
Q4 25
$132.0M
$922.0M
Q3 25
$4.0M
$1.4B
Q2 25
$32.0M
$925.4M
Q1 25
$418.0M
$815.8M
Q4 24
$190.0M
$1.1B
Q3 24
$-31.0M
$1.0B
Q2 24
$111.0M
$173.5M
Q1 24
$422.0M
$1.4B
FCF Margin
NWSA
NWSA
REGN
REGN
Q4 25
5.6%
23.7%
Q3 25
0.2%
37.8%
Q2 25
2.0%
25.2%
Q1 25
20.8%
26.9%
Q4 24
8.5%
28.1%
Q3 24
-1.2%
28.2%
Q2 24
4.3%
4.9%
Q1 24
17.4%
43.8%
Capex Intensity
NWSA
NWSA
REGN
REGN
Q4 25
4.2%
6.4%
Q3 25
3.8%
5.4%
Q2 25
9.6%
6.0%
Q1 25
4.6%
7.6%
Q4 24
2.8%
5.3%
Q3 24
3.7%
6.5%
Q2 24
5.5%
5.1%
Q1 24
4.8%
4.3%
Cash Conversion
NWSA
NWSA
REGN
REGN
Q4 25
1.20×
1.39×
Q3 25
0.76×
1.11×
Q2 25
0.25×
0.82×
Q1 25
4.96×
1.29×
Q4 24
1.17×
1.38×
Q3 24
0.54×
0.96×
Q2 24
5.08×
0.25×
Q1 24
17.97×
2.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NWSA
NWSA

Book Publishing Segment$633.0M27%
Consumer$607.0M26%
News And Information Services Segment$570.0M24%
Real Estate$401.0M17%
Other Product Or Service$173.0M7%

REGN
REGN

Segment breakdown not available.

Related Comparisons